Alex Therapeutics and Navamedic Partner on Parkinson's Disease Companion App

Navamedic, a Nordic pharmaceutical company, announced a new collaboration with Alex Therapeutics. This partnership aims to improve Parkinson's disease management through a new digital health tool. Alex Therapeutics will develop a companion app designed to assist patients using Flexilev®, a prescription medication for Parkinson's disease, in adhering to their treatment regimens.

The upcoming app will enhance medication management by addressing the unique needs of Parkinson's patients. It will work in conjunction with OraFID®, an advanced dose dispenser containing Flexilev®. Together, these tools are expected to offer a comprehensive solution for managing precise and personalized treatment plans, addressing the challenges faced by individuals with Parkinson's disease.

Kathrine Gamborg Andreassen, CEO of Navamedic, expressed enthusiasm about the partnership, highlighting its potential to make Parkinson's treatment more accessible and manageable while easing the burden of daily care for patients. Similarly, John Drakenberg, CEO and Founder of Alex Therapeutics, emphasized the company's commitment to empowering patients with tools for better symptom management and improved quality of life. The companion app is anticipated to launch in Sweden, Norway, and Denmark within the year, with plans for future global expansion.

Click here to read the original news story.